AMBS .062 News out earlier today 1.7 million volume
http://www.amarantus.com/about-us/company-overview
Company Overview
Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.
Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.
AMBS .062 News out earlier today 1.7 million volume
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
OTC Markets Group Achieves Impressive Revenue Growth in 2025
Financial Performance Overview OTC Markets Group Inc. (OTCM) recently reported remarkable financial results for the third quarter of 2025, reflecting significant growth in revenue, operating income, and net profits. This positive performance highlights the company's continuous progress in the dynamic market of U.S. and international securities trading. Key Highlights from...
Continue Reading
Weatherford Delivers Strong 2024 Results Amid Challenges
Weatherford's 2024 Financial Performance Overview Weatherford International plc (NASDAQ: WFRD) has recently shared its fourth quarter and full year results for 2024, highlighting a complex landscape of achievements and hurdles. The financial figures provide a comprehensive understanding of where the company stands amidst fluctuating market conditions. Fourth Quarter...
Continue Reading
EasyA Receives Web3 Foundation Grant for Polkadot University Initiative
EasyA Launches a New Chapter in Web3 Education EasyA, a vibrant platform dedicated to education in Web3, has just secured a significant boost with the 'Decentralized Futures Grant' from the Web3 Foundation. This grant aims to propel their exciting project: the creation of Polkadot University. Supporting Innovators Through Education The primary aim of this project is to...
Continue Reading
New Era Launches Exciting Teamwear Collection with Williams F1
New Era and Atlassian Williams F1 Team Launch New Teamwear In a groundbreaking collaboration, New Era has teamed up with the Atlassian Williams F1 Team to introduce an exciting debut teamwear collection for the upcoming racing season. This innovative partnership merges the rich heritage of American sports culture with the precision and style of British Formula 1...
Continue Reading
Crum & Forster Names Paul Anderson Senior Vice President of Growth
Crum & Forster Announces Paul Anderson's Promotion Crum & Forster (C&F) is proud to announce the promotion of Paul Anderson, an accomplished professional in the insurance industry, to the position of Senior Vice President. In this new role, Anderson will lead the retail Construction segment team. His focus will be on driving strategic growth, fostering innovation, and...
Continue Reading